Sentinel Trust Co. LBA lifted its position in Celgene Co. (NASDAQ:CELG) by 21.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 93,748 shares of the biopharmaceutical company’s stock after buying an additional 16,428 shares during the quarter. Celgene makes up 1.7% of Sentinel Trust Co. LBA’s investment portfolio, making the stock its 11th largest holding. Sentinel Trust Co. LBA’s holdings in Celgene were worth $7,445,000 at the end of the most recent quarter.
Other hedge funds have also recently bought and sold shares of the company. LSV Asset Management raised its stake in Celgene by 23.3% during the 1st quarter. LSV Asset Management now owns 14,300 shares of the biopharmaceutical company’s stock valued at $1,275,000 after acquiring an additional 2,700 shares during the last quarter. Financial Gravity Wealth Inc. purchased a new position in shares of Celgene during the 1st quarter worth approximately $417,000. Marcus Capital LLC raised its stake in shares of Celgene by 85.4% during the 1st quarter. Marcus Capital LLC now owns 5,700 shares of the biopharmaceutical company’s stock worth $508,000 after buying an additional 2,625 shares in the last quarter. Dillon & Associates Inc. raised its stake in shares of Celgene by 18.5% during the 1st quarter. Dillon & Associates Inc. now owns 61,656 shares of the biopharmaceutical company’s stock worth $5,487,000 after buying an additional 9,612 shares in the last quarter. Finally, State of New Jersey Common Pension Fund D raised its stake in shares of Celgene by 14.0% during the 1st quarter. State of New Jersey Common Pension Fund D now owns 570,000 shares of the biopharmaceutical company’s stock worth $50,850,000 after buying an additional 70,000 shares in the last quarter. Hedge funds and other institutional investors own 73.11% of the company’s stock.
A number of equities analysts have recently issued reports on CELG shares. Mizuho reissued a “buy” rating and set a $118.00 target price on shares of Celgene in a research note on Tuesday, July 10th. Zacks Investment Research downgraded Celgene from a “hold” rating to a “sell” rating in a research note on Wednesday, July 18th. BidaskClub raised Celgene from a “sell” rating to a “hold” rating in a research note on Tuesday, July 10th. Morgan Stanley increased their target price on Celgene from $91.00 to $93.00 and gave the company an “equal weight” rating in a report on Friday, July 27th. Finally, Cowen reiterated a “buy” rating and set a $150.00 target price on shares of Celgene in a report on Tuesday, July 10th. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, twenty-one have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $121.42.
NASDAQ:CELG opened at $87.49 on Tuesday. The company has a debt-to-equity ratio of 5.76, a current ratio of 1.52 and a quick ratio of 1.40. Celgene Co. has a one year low of $74.13 and a one year high of $140.20. The stock has a market capitalization of $62.94 billion, a P/E ratio of 12.67, a PEG ratio of 0.54 and a beta of 1.30.
Celgene (NASDAQ:CELG) last issued its earnings results on Thursday, July 26th. The biopharmaceutical company reported $2.16 EPS for the quarter, beating the Zacks’ consensus estimate of $2.11 by $0.05. The company had revenue of $3.81 billion during the quarter, compared to the consensus estimate of $3.70 billion. Celgene had a return on equity of 87.28% and a net margin of 19.81%. Celgene’s quarterly revenue was up 16.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.82 earnings per share. On average, analysts predict that Celgene Co. will post 7.64 EPS for the current year.
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Further Reading: Call Option
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.